NCT Number: NCT01552629
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
The study will assess the safety and efficacy of QGE031 in the treatment of moderate to severe atopic dermatitis patients. In addition, QGE031 levels in the blood will be measured and the effect of QGE031 on markers in the blood and skin will be evaluated. Comparisons of the effect of QGE31 will be made with placebo and also cyclosporine, a treatment already established as being effective in atopic dermatitis.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Novartis Investigative Site, Vienna, Austria
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion criteria:
- Male and female patients 18 to 65 years of age inclusive (at the time of the screening visit), and who passed screening examinations by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests.
- Presence of atopic dermatitis confirmed by itchy skin condition in the past 12 months (must have), plus three, or more, of the following:
- History of involvement of the skin creases (fronts of elbows, behind knees, fronts of ankles, around neck or around eyes)
- Personal history of asthma or hay fever
- History of generally dry skin in the past year
- Onset before age of 2 years
- Visible flexural dermatitis
- Patients with an EASI score of ≥20 at screening and stable AD (not currently experiencing an acute flare of their AD or had a significant change in the extent of their disease or their treatment regimen in the month prior to enrollment)
- Patients with a Total IgE in the range of 30 to 5000 IU/mL inclusive
Key exclusion criteria:
- Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means unless they were using a highly effective method of birth control:
- Total abstinence
- Male/female sterilization
- Combination of any two of the following (a+b or a+c or b+c):
- Use of oral, injected or implanted hormonal methods of contraception
- Placement of an intrauterine device (IUD) or intrauterine system (IUS)
- Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
Treatment and study plan
Placebo
DrugCyclosporine A
DrugPrimary outcomes
-
Change in Eczema Area and Severity Index(EASI)
Time frame: baseline, 12 weeks
Efficacy response will be assessed using EASI.
Secondary outcomes
-
Change in Investigator Global Assessment (IGA) for atopic dermatitis
Time frame: 6 weeks, 12 weeks
Participants dermatitis will be visually assessed and an IGA score will be determined by the Investigator using a prespecified evaluation criteria.
-
Number of participants with adverse events
Time frame: 24 weeks
Adverse events will be determined by observation and non-leading questioning of patients, and by measuring safety parameters (electrocardiograms, clinical laboratory, blood pressure)
-
QGE031 plasma concentrations
Time frame: 24 weeks
Blood samples will be collected on Day 1(predose),15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155, and 169 for determination of QGE031 serum levels
Sponsors and collaborators
Lead sponsor
Novartis Pharmaceuticals
Industry
Registry information
Official study title
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis
Important dates
- Study start
- 2012
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Mar 13, 2012
- Registry last updated
- Feb 23, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
NCT05990725
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Augsburg, Germany
View Trial DetailsStudy of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06585202
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsLong-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Anniston, Alabama, United States
View Trial DetailsTeam-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
NCT03981926
Atopic Dermatitis, Atopic Dermatitis Eczema
Los Angeles, California, United States
View Trial Details